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Abstract
Background The management of rectal cancer has evolved over the years, including the recent rise of Transanal Total Meso-
rectal Excision (TaTME). TaTME addresses the limitations created by the bony confines of the pelvis, bulky tumours, and 
fatty mesorectum, particularly for low rectal cancers. However, guidance is required to ensure safe implementation and to 
avoid the pitfalls and potential major morbidity encountered by the early adopters of TaTME. We report a broad international 
consensus statement, which provides a basis for optimal clinical practice.
Methods Forty international experts were invited to participate based on clinical and academic achievements. The consen-
sus statements were developed using Delphi methodology incorporating three successive rounds. Consensus was defined as 
agreement by 80% or more of the experts.
Results A total of 37 colorectal surgeons from 20 countries and 5 continents (Europe, Asia, North and South America, Aus-
tralasia) contributed to the consensus. Participation to the iterative Delphi rounds was 100%. An expert radiologist, patholo-
gist, and medical oncologist provided recommendations to maximize relevance to current practice. Consensus was obtained 
on all seven different chapters: patient selection and surgical indication, perioperative management, patient positioning and 
operating room set up, surgical technique, devices and instruments, pelvic anatomy, TaTME training, and outcomes analysis.
Conclusions This multidisciplinary consensus statement achieved more than 80% approval and can thus be graded as strong 
recommendation, yet acknowledging the current lack of high level evidence. It provides the best possible guidance for safe 
implementation and practice of Transanal Total Mesorectal Excision.
Keywords Rectal cancer · Transanal total mesorectal excision · Guidelines · Oncology
The management of rectal cancer has evolved over the 
years with several options available to physicians taking 
care of cancer patients, including refined neoadjuvant and 
adjuvant therapies and various surgical techniques. Among 
the newly developed surgical approaches to rectal cancer, 
transanal total mesorectal excision (TaTME) proposes to 
address the anatomical limitations of the bony confines of 
the pelvis, bulky tumours, and fatty mesorectum through a 
new approach. Indeed, while taking advantage of the mag-
nification of a laparoscope, performing a total mesorectal 
excision through the anus may confer a number of benefits. 
In particular a different viewpoint with a facilitated excision 
of the lower third of the mesorectum, better visualization 
of the endangered structures during dissection, and poten-
tially a safer anastomosis by avoiding the multiple stapler 
firings too often required in a conventional complete anterior 
approach. Following the first live case in 2009 and inspiring 
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experience of the pioneers [1, 2], dissemination of TaTME is 
taking place swiftly with many institutions having adopted 
this technique and published encouraging results. A large, 
international registry documents the adoption and practice 
of TaTME, with more than 2500 procedures from 39 dif-
ferent countries and 128 active centres recorded so far [3]. 
Furthermore, two international randomised controlled trials 
from the COLOR [4] and GRECCAR [5] investigators have 
recently started, randomising patients between TaTME and 
conventional laparoscopic TME. COLOR III [4] and GREC-
CAR 11 [5] are expected to help define the place and true 
value of TaTME in the surgical armamentarium for mid and 
low rectal cancer. Meanwhile, guidance is required to ensure 
safe implementation of TaTME, avoiding the pitfalls and 
intra-operative complications encountered and overcome by 
the pioneers and early adopters of this promising technique. 
The objectives of this international and interdisciplinary 
consensus statement are three-fold:
1. to provide a framework and guidance to those embark-
ing on TaTME, including patient selection and surgical 
indication, technique, and educational opportunities;
2. to highlight the challenges, benefits, and distinctive dan-
gers of this technique, capitalizing on a large interna-
tional experience of early adopters of TaTME;
3. to promote prospective outcomes analysis and participa-
tion into clinical trials and registries.
Hence, it is hoped that the present international consensus 
guidelines will provide a basis for optimal clinical practice.
Materials and methods
Sponsor and potential conflict of interest
The consensus was sponsored by the European Colorectal 
Congress of St.Gallen, Switzerland (http://www.colorec-
talsurgery.eu), which covered all costs associated with the 
entire consensus process with no support or involvement 
from the medical industry. The European Colorectal Con-
gress is organizing one of the three largest colorectal con-
gresses worldwide with an attendance of over 1400 partici-
pants from 80 countries (2016). It has no corporate sponsor, 
no member of the medical industry on its Board, and it does 
not own stock or participation to any medical company.
The four core authors of the consensus ensured scientific 
integrity. They completed the International Committee of 
Medical Journal Editors (http://www.icmje.org) form for dis-
closure of potential conflict of interest, reporting nothing to 
disclose. They were not paid for their time and efforts. The 
single benefit granted to the 40 consensus experts beyond 
collaborative authorship was not having to pay to attend the 
European Colorectal Congress in 2016.
Importantly, all statements referring to devices and instru-
ments used to perform TaTME have been generated by the 
four core authors, in agreement with the current literature 
and routine practice of most experts. Referring to a given 
product and its alternatives does not imply endorsement 
of any manufacturer, it does solely provide the techni-
cal guidance based on the experience of a large group of 
international experts that may be expected by readers of the 
consensus.
Consensus development
The consensus process was based on current recommenda-
tions for guideline developments adapted to the question 
at hand [6]. The core authors of the consensus drafted its 
agenda and formulated the initial questions with a focus on 
current practice, areas of controversy, and educational per-
spective. They identified and invited a group of international 
experts based on their clinical and academic achievements 
in the field of rectal cancer surgery and TaTME. Experts 
had performed at least 20 TaTME cases and reported their 
results in peer-reviewed publications and registries. They 
were major contributors to the international Low Rectal 
Cancer taTME registry (http://www.lorec.nhs.uk) having 
reported together more than 1000 TaTME procedures. An 
expert pathologist, radiologist, and medical oncologist were 
invited to participate to ensure the highest standard of care 
from a multidisciplinary team in the recommendations of 
the consensus.
The consensus statements were developed using a Del-
phi methodology [7] incorporating three successive rounds. 
The first two consecutive rounds were web-based with 
anonymous voting, and explicitly asked for feedback and 
suggestions from the international experts. The comments 
recorded were included into the iterative development of 
the consensus statements. The third round was a dedicated 
expert meeting during the European Colorectal Congress in 
St.Gallen on November 30th, 2016 with face-to-face open 
discussion and finalisation of the consensus document. Con-
sensus was defined as agreement by 80% or more of the 
experts. The final manuscript was then drafted by the four 
convenors of the consensus with only minor editing of the 
consensus statements if required. The discussion further 
developed practical advice, including perspectives from the 
expert radiologist and oncologist. The final consensus docu-
ment was reviewed and approved by all involved experts.
Regarding the paucity of clinical data published on 
TaTME, no formal grading of evidence was provided. The 
authors of most major cohort series on TaTME were experts 
of the present consensus. Recommendation strength of the 
consensus statements was graded according to the Grading 
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of Recommendations, Assessment, Development and Evalu-
ation system (GRADE) [6]. Unresolved controversies and 
discussion points complete each section of the consensus.
An update of the present consensus and systematic review 
of the literature is planned within three years by the core 
authors.
Results
Forty international experts were invited to participate in 
the consensus process. Two experts delegated participation 
to another senior staff surgeon who fulfilled the expertise 
criteria defined. A total of 37 colorectal surgeons from 20 
countries in 5 continents (Europe, Asia, North and South 
America, Australasia) contributed to the work. The per-
centage reported in the consensus statements refers to those 
37 (100%) expert colorectal surgeons. Participation to the 
first 2 web-based Delphi rounds was 100%, while 30 of 37 
(81.1%) colorectal surgeons attended the third round live. 
The remaining 7 experts who could not attend the third 
round in person, televoted on the revised statements, achiev-
ing 100% participation to the third round. The consensus 
panel included three additional experts from the fields of 
clinical histopathology, radiology, and medical oncology. 
All 40 experts approved the final version of the manuscript.
Consensus statements
Patient selection and surgical indications
Both genders can be operated on by a transanal approach. 
The female pelvis tends to be broader and therefore allows 
for an easier mesorectal excision. Obesity, especially vis-
ceral obesity with a fatty mesorectum, is an important limi-
tation. Lastly, bulky mid/distal rectal tumours are very chal-
lenging, in both female and male patients. Hence, a TaTME 
may be technically easier than an abdominal TME in patients 
with a narrow pelvis, obese patients, and patients bearing a 
bulky mid/distal rectal tumour.
37/37 = 100%
In males, the prostatic urethra is at risk during the dissec-
tion of the lower third of the rectum. Injury to the prostatic 
urethra, especially when the pelvis has been irradiated, is a 
major complication.
37/37 = 100%
In females, the vagina is at risk of injury during the dis-
section of the lower third of the rectum. This lesion can be 
directly repaired with simple sutures, even in an irradiated 
pelvis. Caution must be taken when fashioning the anas-
tomosis to avoid the dreaded complication of a neorecto-
vaginal fistula.
37/37 = 100%
Prior pelvic surgeries make any total mesorectal excision 
more difficult, irrespective of the abdominal or transanal 
approach. Operating on patients with a prior prostatectomy, 
especially for an anterior rectal cancer with close circum-
ferential resection margin (CRM), can be challenging. Prior 
mesh rectopexy may also pose greater surgical challenges. 
A prior hysterectomy is usually not a limitation.
34/37 = 91.9%
No further gender limitation/preference were felt relevant.
37/37 = 100%
There are no given body mass index (BMI) or limitation 
in BMI which make TaTME much better than open/laparo-
scopic/robotic TME.
37/37 = 100%
There is no given hip-waist ratio which makes TaTME 
much better than open/laparoscopic/robotic TME.
37/37 = 100%
Rectal cancer height
Transanal total mesorectal excision is best for lower rec-
tal resections. It can be performed for partial mesorectal 
excision, e.g. for a cancer of the upper third of the rectum, 
although the need for an endoscopic purse-string placement 
on the long rectal stump increases the technical challenges. 
Caution should be taken not to perform unnecessary total 
mesorectal excision. The minimum distal margin of 1 cm 
applies to lower third cancers, whereas upper and middle 
third cancers require a distal margin of 5 cm. A partial meso-
rectal excision can be safely performed for cancer of the 
upper third of the rectum, whereas a total mesorectal exci-
sion is required for cancer of the mid and lower third.
32/37 = 86.5%
When an abdominoperineal excision is indicated, a 
“transperineal TaTME approach” may be undertaken once 
the surgeon has sufficient expertise in TaTME.
32/37 = 86.5%
Potential benefits of a “transperineal TaTME approach” 
include tailoring the dissection to the oncologic needs and 
avoiding the need to flip the patient in prone position in 
order to obtain an accurate view of the anterior plane.
34/37 = 91.9%
An intersphincteric TaTME can also be performed, 
thereby preserving some of the sphincter function. The 
known benefits of TaTME then apply, particularly better 
visualization of the lower two-thirds of the rectum when dis-
secting upwards. An intersphincteric TaTME requires, how-
ever, a coloanal or colo-pouch-anal handsewn anastomosis 
and the corresponding surgical expertise. Furthermore, the 
anterior dissection can be very difficult in an intersphincteric 
resection placing the urethra at risk.
37/37 = 100%
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Surgical indications beyond rectal cancer
Beyond the classical surgical indication for neoplastic dis-
ease, TaTME can be performed in the context of inflamma-
tory bowel disease. A proctectomy alone or a proctocolec-
tomy can be performed, with or without ileal pouch anal 
anastomosis. For benign diseases, especially when a pouch 
reconstruction is considered, dissection of the rectum close 
to the bowel wall is an option that offers better function.
36/37 = 97.3%
Pouch advancement procedures, the dissection/removal 
of a neorectum in cases of chronic anastomotic sinus/anas-
tomotic leak, and proctectomy for rectovaginal fistula are 
advanced procedures which can be performed transanally 
if appropriate technical and surgical expertise is available. 
The underlying disease, local inflammation, and dissection 
through scar tissue and obscured planes may be challenging.
37/37 = 100%
Perioperative management
Enhanced recovery
The recommendations for the perioperative management of 
TaTME patients follow the principles of enhanced recovery 
pathways (ERAS). The ERAS society has published in 2013 
its guidelines for perioperative care in elective rectal/pelvic 
surgery [8], which the present group of experts endorses and 
recommends for the safe practice of TaTME.
36/37 = 97.3%
Mechanical bowel preparation
Full mechanical bowel preparation in all patients in whom a 
total mesorectal excision is planned is recommended, irre-
spective of the use of a diverting ostomy [9, 10].
33/37 = 89.2%
Pelvic drain
Evidence is scarce to use a routine pelvic drain after TaTME. 
Its use depends mainly on the surgeon’s preference.
34/37 = 91.9%
Urinary catheter
A urinary catheter can be removed safely on the first post-
operative day with low catheter reinsertion rates, includ-
ing in elderly males. Epidural analgesia does not prevent 
early catheter removal. A suprapubic catheter is a good 
option whenever prolonged postoperative urinary drainage 
is anticipated.
30/37 = 81.1%
Perioperative antibiotic prophylaxis
Perioperative antibiotic prophylaxis and its repetition during 
the operation are mandatory and follow institutional guide-
lines. There is no evidence to support an extended periopera-
tive antibiotic prophylaxis beyond 24 h.
37/37 = 100%
Patient positioning and operative room set‑up
Patient preparation
The standard set-up may vary. However, a lithotomy posi-
tion (or modified Lloyds-Davies position) is mandatory to 
allow a good position and exposition for the abdominal and 
perineal teams.
37/37 = 100%
Insertion of a urinary catheter, particularly in males, is 
advised. It may help to achieve a safer anterior dissection. 
In addition, by withdrawing the transanal platform, it allows 
palpation of the prostatic urethra in case of doubt.
34/37 = 91.9%
A generous rectal washout is advised after completing 
the pursestring and before starting the transanal dissection.
30/37 = 81.1%
One versus two‑team approaches
A one or two-team procedure can be performed and both 
have their advantages and disadvantages [11]. The two-team 
approach is costlier, at least in terms of personnel (two surgi-
cal and scrub teams). However, it should save at least 30 min 
of operative time and in case of difficult dissection it allows 
a better visualization and the two operating surgeons can 
help each other.
33/37 = 89.2%
The consensus panel advises to operate with two teams 
simultaneously whenever possible. Yet, a single operating 
team switching between abdominal and transanal approaches 
can also be very effective.
37/37 = 100%
On the other hand, a two-team approach requires a good 
collaboration between the abdominal and perineal teams. 
An integrated operative theatre should be advised to assure 
a good view of the screens. Space around the patient may 
be, however, an issue when two complete operative teams 
work synchronously.
30/37 = 81.1%
For a one-team approach, the benefits of starting the 
TaTME abdominally include exclusion of a peritoneal car-
cinomatosis, early splenic flexure mobilization and vascular 
control, and easier identification of the left ureter and auto-
nomic nerves at the promontory level. In addition, the risk 
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of massive distension of the colon (due to insufficiency of 
the rectal purse-string) is reduced.
32/37 = 86.5%
In a one-team approach, initiating the pelvic dissection 
from above does not seem to limit the extent and quality of 
the pneumopelvis.
35/37 = 94.6%
When starting the TaTME transanally, a crucial point in 
the operation is swiftly securing an air-tight purse-string. 
This avoids stool contamination, cancer cell spillage, and 
bowel dilatation.
37/37 = 100%
Starting the TaTME transanally allows for an exact tran-
section point of the rectum assuring correct assessment of 
the distal margin.
32/37 = 86.5%
Devices and instruments
Scope
A 10 mm high definition scope is preferred as it offers a 
broader visual field. For the transanal dissection, a 30° scope 
is recommended. A 3D system allows superior depth visuali-
zation; however, it is routinely used only in a few centres as 
there is a lack of data on reported clinical benefits.
32/37 = 86.5%
For the abdominal part, a 5 mm or a 10 mm scope may 
be used. Ten millimetres scopes offer a broader and brighter 
view.
37/37 = 100%.
Transanal access platforms
A stable transanal access platform is required to ensure a 
pneumorectum and insertion of three ports. Most experts use 
a GelPOINT Path access platform (Applied Medical, Rancho 
Santa Margarita, CA, USA) inserted transanally [12]. Many 
alternative platforms from major suppliers exist (DalimSurg-
Net, Ethicon, Medtronic, Olympus, Storz, Wolff, etc).
34/37 = 91.9%
When performing an abdominoperineal excision, a 
transanal access platform is inserted when the dissection 
reaches the depth of the levator ani.
32/37 = 91.1%
Alternative platforms may be used depending on the sur-
geon’s preference. The expert panel has limited experience 
with alternative platforms, and hence specific recommenda-
tion on these cannot be made (e.g. some experts supported 
TEO Storz (59.5%, Tuttlingen, Germany), TEM Wolff 
(40.5%, Knittlingen, Germany), Octo-Port (21.6%, Dalim-
SurgNet, Seoul, Korea), etc).
33/37 = 89.2%
Anal retraction sutures or an anal retractor system (most 
experts used a Lone Star retractor, CooperSurgical, Trum-
bull, CT, USA) may prove useful, especially when perform-
ing a handsewn anastomosis.
36/37 = 97.3%
Insufflation
Transanal  CO2 insufflation should ensure a stable pneumo-
rectum/pneumopelvis under continuous smoke evacuation, 
a much helpful feature as the transanal dissection occurs 
close to the scope [13]. Most experts used an Airseal system 
(CONMED, Utica, NY, USA) for this purpose.
The abdominal part of the procedure may use a standard 
insufflator. Alternatively, two standard air insufflators can be 
used concurrently for the transanal and the transabdominal 
stages. However, the transanal insufflator should be able to 
deliver high insufflation pressure to compensate for frequent 
to constant smoke evacuation.
33/37 = 89.2%
The pneumorectum is typically initiated through an access 
port using low pressure/low smoke evacuation levels. It is 
important to occlude the rectal lumen with an abdominal 
clamp until the pursestring is completed and the rectal dis-
section is started. Upon progression of the rectal dissection a 
higher  CO2 pressure and smoke evacuation level are required, 
up to 20 mmHg. For a standard high insufflation pressure the 
recommended abdominal pressure is 12–15 mmHg.
32/37 = 86.5%
Laparoscopic instruments
Standard laparoscopic instruments are used for the transa-
nal dissection. Monopolar cautery is used most frequently; 
alternatively, an energy device can be used, although this 
may further increase the procedure cost.
31/37 = 83.8%
The panel selected monopolar and bipolar cautery as the 
preferred energy source for the transanal dissection. Of all other 
energy sources (bipolar sealing device, ultrasonic shears, or a 
combination thereof in a single instrument), ultrasonic shears 
were used by a minority (2/37 = 4.6%) for transanal dissection.
35/37 = 94.6%
Curved/angulated instruments may be useful.
30/37 = 81.8%
Transanal extraction of the specimen using a wound 
protector may be envisaged, depending on the size of the 
tumour and the bulkiness of the specimen. However, avoid-
ing an abdominal extraction incision must be balanced 
against the risk of damage to both the sphincter complex 
and the specimen in a transanal extraction.
36/37 = 97.3%
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When extracting the specimen through an abdominal inci-
sion, a wound protector should be used to prevent port site 
metastases and wound infection.
37/37 = 100%
Pelvic anatomy revisited: the transanal perspective
Recognizing visual clues and orientating oneself are at the 
core of a safe surgical procedure [14]. The pelvic anatomy 
seen through the transanal perspective is novel even to expe-
rienced surgeons. Several pitfalls may arise from leaving the 
correct plane. Early recognition of errors and return to the 
correct plane are crucial to a safe TaTME dissection.
37/37 = 100%
In females, the anterior dissection carries the risk of 
entering the vagina. Usually, this injury can be easily rec-
ognized and repaired as required.
36/37 = 97.3%
The urethra in males may be injured during the initial 
anterior dissection.
35/37 = 94.6%
If in doubt, the transanal platform should be removed 
and the prostate/prostatic urethra/urinary catheter palpated 
to confirm the correct dissection plane.
34/37 = 91.9%
There is a risk of following a perimuscular plane and 
therefore being too close to the rectum and/or cancer. This 
is especially true at the beginning of the transanal dissection, 
when caution should be undertaken to identify and proceed 
early within the TME plane.
36/37 = 97.3%
Pneumopelvis may create areolar planes beyond the dis-
section point thus leading the surgeon astray.
36/37 = 97.3%
The ureters are particularly at risk of injury during the 
anterolateral dissection, especially when the lateral dis-
section is carried out too widely without control from an 
abdominal surgeon.
32/37 = 86.5%
Caution should be undertaken to avoid too lateral a dis-
section during the transanal approach, because of the risk of 
injury to the pelvic side wall and its structures.
37/37 = 100%
Posteriorly, too deep a plane runs the risk of entering 
the presacral space with possible subsequent injury to the 
presacral venous plexus.
36/37 = 97.3%
For low rectal tumours, an (total or partial) intersphinc-
teric dissection may be required but carries the risk of poor 
function.
35/37 = 94.6%
TaTME training
Courses, proctoring and mentoring
TaTME represents an important addition to the contempo-
rary treatment of rectal pathologies. In particular, it has the 
potential to improve the outcomes in rectal cancer surgery. 
However, the safe and successful introduction and develop-
ment of TaTME requires adequate training. Participation in 
dedicated courses, including hands-on/cadaveric courses, 
taking part in a mentoring/proctoring program, and perform-
ing initial TaTME cases under supervision are crucial steps 
in the safe learning and implementation of TaTME.
37/37 = 100%
The consensus panel advises to participate in a TaTME 
course prior to performing any TaTME cases in the clini-
cal setting. A TaTME course should include peer-reviewed 
materials covering pelvic anatomy from the transanal per-
spective, surgical technique of TaTME, pitfalls, and techni-
cal troubleshooting.
37/37 = 100%
Furthermore, it is important for the whole multidiscipli-
nary team to know the particulars of TaTME. Case obser-
vation and hospital visit, involving one’s complete theatre 
team, are very useful prior to starting one’s first TaTME.
37/37 = 100%
In addition to case observation, mentoring/proctoring 
with an expert surgeon available is strongly advised.
36/37 = 97.3%
An important further prerequisite is adequate experience 
in oncological rectal surgery, including an annual centre vol-
ume of at least 10 cases.
36/37 = 97.3%
The learning curve for safe and independent practice of 
TaTME is yet to be established but progress is slow even for 
the experienced laparoscopic colorectal surgeon. Depend-
ing on previous laparoscopic TME and TEM/TAMIS expe-
rience, 1–5 TaTME cases should be proctored/supervised 
before embarking on solo practice.
35/37 = 94.6%
The panel agrees that the overall learning curve is long 
and demanding, with more than 20 cases required. No con-
sensus could be reached on a given number of procedures 
to reach proficiency.
37/37 = 100%
Prospective monitoring and benchmarking one’s own out-
comes is advised, as well as participation in clinical studies. 
In particular, perioperative clinical outcomes, oncological 
outcomes, and function/quality of life should be monitored 
in an effort to continuously improve quality.
37/37 = 100%
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Surgical technique step by step
The consensus panel endorses a standardized surgical tech-
nique to allow for safe and reproducible outcomes. Several 
publications have described ad hoc surgical techniques 
and variations in performing TaTME. In the context of an 
upcoming randomised controlled trial evaluating TaTME 
vs laparoscopic TME (COLOR III), a step by step TaTME 
procedure has been validated and published. This consen-
sus panel recommends adherence to the surgical technique 
described in the COLOR III protocol [15].
34/37 = 91.9%
TaTME starts with either the transabdominal or transanal 
phase. In the abdominal phase the sigmoid and the splenic 
flexure are mobilised by multiport laparoscopy or through 
single port surgery with the single port located in the future 
ileostomy site. The inferior mesenteric artery is centrally 
ligated after identification of the left ureter. After mobili-
sation of the descending colon, sigmoid and the proximal 
rectum, the transanal phase is initiated.
In a two-team approach, the lumen of the distal sig-
moid colon is occluded early with a grasper to minimize 
colonic distension while the perineal surgeon completes the 
pursestring.
31/37 = 83.8%
The transanal phase starts with a washout of the rectum 
with a povidone-iodine solution [16, 17]. Use of anal retrac-
tion sutures and/or an anal retractor are advised.
37/37 = 100%
For distal tumours (< 5 cm from the anal verge), an inter-
sphincteric dissection is performed with the use of an anal 
retractor. The transanal dissection is continued as proximal 
as possible in open fashion. Thereafter, the open rectum is 
closed with purse-string suture to prevent spillage of bacteria 
and tumour cells.
33/37 = 89.2%
In case of tumours above 5 cm from the anal verge, a 
transanal platform is inserted and sutured to the perineal 
skin. The rectal stump is then closed with a pursestring 
suture with a recommended minimum distance of 1 cm from 
the distal end of the cancer. This pursestring suture can be 
placed through the transanal platform under direct vision or 
endoscopically, especially for more proximal tumours.
32/37 = 86.5%
A pneumorectum is created with carbon dioxide at a pres-
sure of 14 mmHg and a relatively low flow of 5 l per minute 
to minimise rectal contractions. When dissection progresses, 
insufflation settings can be increased and air evacuation con-
trolled to allow for the best possible visualization. Use of a 
dedicated insufflation management system, which provides 
a stable pneumopelvis under continuous smoke evacuation, 
is advised.
34/37 = 91.9%
Dissection starts by marking the distal resection level 
with the diathermy hook, then proceeding to a full thickness 
incision of the rectal wall. The dorsal plane is then devel-
oped proximally using blunt and cautery dissection along the 
TME plane. The ventral dissection comes next, taking great 
care not to injure the vagina and to preserve the prostatic 
urethra. The lateral dissection comes last after progression 
of the dorsal and ventral parts, in order to minimize the risk 
of damaging neurovascular structures. Lastly, the peritoneal 
reflection is opened. This step should be carried out last as it 
may markedly impair the ability to maintain a pneumopelvis.
30/37 = 81.1%
Whenever restoration of bowel continuity is envisaged, 
construction of a diversion ileostomy is advisable to protect 
against and minimize the risk of anastomotic leak [18, 19].
33/37 = 89.2%
There are different techniques to perform a low anastomo-
sis after TaTME. If an intersphincteric dissection was per-
formed, a handsewn coloanal anastomosis is the best option.
37/37 = 100%
On the other hand, if there is enough distal rectum to perform 
a pursestring, a stapled anastomosis can be safely performed.
35/37 = 94.6%
Different anastomotic techniques have been published 
[20] and seem feasible and safe. To date, there is no strong 
evidence supporting one particular technique. All stapled 
anastomoses use a double pursestring technique placed at the 
rectal stump and at the colonic end. Multiple stapler firings 
with crossing staple lines is thus avoided. The diameter of 
the stapler varies from 28 to 33 mm.
36/37 = 97.3%
The type of reconstruction depends on the surgeon’s pref-
erence and the patient’s anatomy (end-to-end or side-to-end 
anastomosis, or colonic J pouch). There is limited data sug-
gesting better short-term functional outcomes with a side-
to-end or colonic J pouch reconstruction.
35/37 = 94.6%
Depending on the size of the specimen, an abdominal or a 
transanal extraction can be performed. A transanal extraction 
reduces the risk of postoperative abdominal wall compli-
cations (pain, wound infection, incisional hernia). It may, 
however, put additional stretch on the anal sphincter and can 
cause trauma to the rectal specimen.
34/37 = 91.9%
However, there are cases where a transanal extraction is 
not possible or suitable (short mesentery, bulky specimen, 
risk of specimen injury). In this situation, a suprapubic or 
short midline incision is advised.
33/37 = 89.2%
In all cases, a wound protector should be used to reduce 
the potential risk of wound infection and tumour cell 
implantation.
35/37 = 94.6%
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Outcome analysis
Outcome research
Several publications from expert centres have shown promis-
ing results and have supported the dissemination of TaTME. 
The consensus panel encourages the prospective monitoring 
of perioperative clinical outcomes, histopathology results, 
oncological outcomes, and function/quality of life.
37/37 = 100%
Clinical outcomes of interest include operative time, one-
team or two-team procedure, conversion to laparoscopy, 
conversion to open surgery, 30-day post-operative morbid-
ity taking advantage of a validated grading system (e.g. 
the Dindo-Clavien classification [21]), length of hospital 
stay, and readmission. Anastomotic leaks should be graded 
according to the international grading system (A–C) [22]. 
Whether a case has been proctored should also be recorded.
37/37 = 100%
Oncologic outcomes of interest include quantification 
of resection margins (proximal, distal, and circumferential 
resection margins), Quirke/Mercury TME quality grading 
[23], TNM staging [24], including the number of lymph 
nodes retrieved, and both neoadjuvant and adjuvant treat-
ment. Recurrence rates shall be monitored prospectively as 
well.
37/37 = 100%
Functional outcomes of interest include generic and 
colorectal cancer specific assessment of quality of life (e.g. 
EORTC QLQ-C30 & CR-29 [25]), urinary function (e.g. 
IPSS [26]), gender specific sexual function (e.g. IIEF-5 [27]/ 
FSFI-6 [28]), bowel function (e.g. LARS [29], Vaizey [30]), 
and health utility (e.g. EQ-5D [31]).
36/37 = 97.3%
Lastly, econometric analysis may be of interest, including 
assessment of health utilities (e.g. EQ-5D [31]), procedure 
and hospital costs, and hospital reimbursement.
37/37 = 100%
Registries and clinical trials
The consensus panel strongly advises participation in the 
international TaTME registry [3] (http://www.TaTME.sur-
gery) and in the randomised controlled trials COLOR III 
[4] and GRECCAR 11 [5] (TaTME vs laparoscopic TME).
37/37 = 100%
MRI staging and prognosis information
Gina Brown, Consultant Radiologist
Multidisciplinary review of MRI rectal cancer findings 
leads to improved outcomes [32]. Thus, MRI is the investi-
gation of choice for local staging of rectal cancer. It shows 
the extension of the tumor through the rectal wall and to the 
mesorectal fascia, and the involvement of local nodes and 
vessels [33, 34]. Further, MRI enables an objective assess-
ment of the tumour with respect to the sphincter and the anal 
verge, guiding management decisions regarding potential 
sphincter preservation [35]. Understanding the relationship 
of the tumour to the distal TME plane at or just above the 
puborectalis sling prevents inadvertent surgical perforation 
and dissemination of tumour during distal TME dissection. 
Also, it allows selective use of extralevator abdominoperinal 
excision for those tumours where the invasive border lies 
within 1 mm of the intersphincteric plane, levator muscle, 
or lower prostate [36, 37]. Last, MRI assessment reveals 
the area or quadrant of maximal tumour at risk of margin 
involvement [36].
Other prognostic and predictive factors that are assessed 
include depth of extramural spread (mrT substage) [38, 39] 
and the presence or absence of tumour signal into extramural 
veins [40–42]. High resolution MRI technique enables char-
acterisation of nodes based on breach of the nodal capsule 
and/or replacement of nodal tissue by tumour resulting in 
border irregularity and mixed signal intensity respectively. 
Size criteria should not be used [34, 43]. Compared with 
the assessment of mrCRM (TME plane), millimetre assess-
ment of the extramural depth of spread, and MRI assessment 
of venous invasion, MRI assessment of nodes do not hold 
prognostic significance [44]. Reporting standards for MRI 
staging are shown in Table 1.
A word of caution by the pathologist
Philip Quirke, Consultant Pathologist
As any new technique, TaTME needs rigorous evalua-
tion and its safety needs to be proven. Pathology is help-
ful in evaluating its effectiveness and optimizing surgical 
technique. Major changes in local recurrence and survival 
in rectal cancer have been achieved by considering the 
anatomy of the rectum, careful selection of the appropriate 
planes on MRI, assessing the surgeon’s ability to deliver the 
appropriate anatomical package and quality assurance by the 
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pathologist through describing the involved margin rate [45] 
and the quality of the surgery [23, 46, 47].
The anatomy is difficult as posteriorly there are complex 
changes in the angulation of the mesorectal fascial plane and 
the mesorectum is initially a thin fatty layer. Anteriorly there 
is very little mesorectum and the anterior surgical margin is 
in juxtaposition to the urethra. In the male important nerves 
run at the height of the prostate, so surgery needs to be very 
precise. It is essential that the surgeon finds and develops the 
correct plane around the tumour and stays within it. Since 
the height of the tumour is an important factor with lower 
tumours generating worse surgical planes [47] there may 
well be a place for excellent TaTME but this needs to be 
proven. The degree of increased operative difficulty caused 
by preoperative therapy also needs to be determined.
Auditing of key pathology features safeguards the quality 
of the surgical planes, especially anteriorly in the low rec-
tum, and the frequency of CRM positivity. Photography of 
the anterior and posterior surfaces of all TaTMEs is essen-
tial to alert surgeons to suboptimal planes and ensure their 
correction in future cases. Photography allows for external 
audit and evidence rather than opinion based audit. Early, 
self-declared registry information looks optimistic [48] but 
this is no substitute for proper cohort studies with central 
pathology evaluation and MRI stratified randomised trials.
Multimodal therapy and role 
of the multidisciplinary team
Ulrich Güller, Consultant Medical Oncologist
Multimodal therapy and multidisciplinary tumour board 
discussions resulted in a quantum leap regarding out-
comes of rectal cancer patients. However, major challenges 
still lay ahead: First, while local relapses have become a 
rare phenomenon in patients undergoing neoadjuvant 
chemo-radiotherapy and proper TME, distant metastases 
remain an unsettling problem. Hence, further efforts must 
focus on improving systemic treatment. Second, not all 
patients need the trimodal therapy including radiation, sur-
gery, and chemotherapy. Currently, randomised trials are 
evaluating whether patients with good response to neoad-
juvant chemotherapy can do without additional radiation 
(PROSPECT Trial, Alliance) [49]. Moreover, the use and 
time point of chemotherapy are further evaluated as it is 
hypothesized that systemic treatment is used too late in 
the treatment sequence leading to a higher risk of distant 
relapse. Contemporary randomised controlled trials now 
evaluate total neoadjuvant treatment (e.g. Rapido Trial 
[50]), in which patients receive chemotherapy in a neoadju-
vant setting. Finally, not all patients must undergo surgery. 
As pioneered by Habr-Gama [51], a relevant fraction of 
patients having a complete clinical response after neoadju-
vant therapy can be followed without immediate operation, 
with good outcomes, including improved quality of life and 
decreased morbidity, as the recent presentation at ASCO GI 
2017 of the International Watch and Wait Database (IWWD) 
for Rectal Cancer confirms [52]. To further advance care 
and knowledge in treating rectal cancer patients, it is of car-
dinal importance to nurture an ongoing collaboration with 
all actively involved disciplines including surgery, radiation 
oncology, gastroenterology, pathology, radiology and medi-
cal oncology.
Discussion
The primary objective of this interdisciplinary consensus 
statement was to provide guidance to those embarking on 
TaTME. Secondary, it was aimed to highlight the challenges, 
Table 1  Reporting standards for MRI staging
MRI reporting standards
Site of tumour—upper/mid/lower third
Height from puborectalis sling and anal verge and craniocaudal length
For tumours arising at or within 2 cm above the level of the puborectalis sling—assessment of the safety of the total mesorectal excision (TME) 
surgical plane
Relationship to important landmarks, e.g., peritoneal reflection/seminal vesicles
Morphology: e.g. annular/semi-annular/mucinous
Infiltrating border—smooth or nodular infiltration
Presence or absence of extramural venous invasion
Presence or abscence of vascular mediate tumour deposits (N1c)
Maximum depth of extramural spread
Presence or absence of malignant lymph nodes (smooth border/uniform signal = benign irrespective of size)
Minimum distance to mesorectal fascia or intersphincteric plane > 1 mm = mrCRM clear
In the final assessment, the TNM stage and an assessment of potential resection margin involvement/safety of the TME plane (classified as 
potentially involved if tumour < 1 mm to the mesorectal fascia/ intersphincteric plane) should be made
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benefits, and distinctive dangers of this technique, and to 
promote prospective outcomes analysis.
Seven different aspects were analysed including: patient 
selection and indication, perioperative management, 
patient positioning and operating room set up, devices 
and instruments, pelvic anatomy, TaTME training, and 
outcomes analysis. Globally, the statements achieved 
more than 80% approval for most of these items, which 
were graded as strong recommendations. However, it is 
acknowledged that there is a current lack of high level 
evidence in support of this recommendation, which is 
based only on expert opinion. On the other hand, the panel 
of experts found a large agreement on all the different 
questions.
As for recommendations, the GRADE guidelines [6] 
state: ‘Strong recommendations indicate that the panel is 
confident that the desirable effects of adherence to a recom-
mendation outweigh the undesirable effects. Weak recom-
mendations indicate that the desirable effects of adherence 
to a recommendation probably outweigh the undesirable 
effects, but the panel is less confident’. Recommendations 
were based not only on the quality of evidence but also on 
the balance between wanted and unwanted effects, and on 
values and preferences [53]. The latter implies that, in some 
instances, strong recommendations may be reached from 
low-quality data and vice versa.
The introduction of a new technique must occur in a safe 
and controlled manner to protect both the patient and the 
surgeon. The expert panel agreed that the earlier stages of 
the learning curve are best overcome by initially selecting 
easier cases, although no agreement was reached on gender 
selection with 60% of the panel favouring the broader pel-
vis of female patients to begin with TaTME. However, the 
panel acknowledges that the greater the BMI and/or more 
unfavourable the hip-waist ratio the more TaTME helps to 
overcome the challenges of an oncologic low pelvic dis-
section. This is particularly true in male patients with low 
rectal cancer.
The adoption of TaTME has seen an exponential growth 
worldwide. The largest cohort to date includes recently 
published results from the International TaTME registry, 
suggesting an oncologically safe and effective technique 
with acceptable short-term clinical outcomes [48]. How-
ever, surgeons did experience intra-operative equipment 
and technical difficulties in up to 40% of cases, with 
incorrect plane dissection, pelvic bleeding, unstable pneu-
mopelvis and, more worryingly, visceral injuries such as 
urethral division. Indeed, one of the most dreaded specific 
complication of TaTME is the injury of the urethra during 
initial anterior dissection. The TaTME surgeon has to rec-
ognize new landmarks in dissection and think in different 
planes. The prostate may initially appear as a vertical wall 
in front of the dissection and inadvertently be dissected en 
bloc with the anterior mesorectum or ‘dug’ into, causing 
urethral injury. Removing the platform to palpate and help 
define the anatomy of the prostate/urethra or vagina is a 
key step in case of doubt. Similarly, for very low tumours 
where dissection is initiated in an intersphincteric plane 
the platform may be inserted once a classical transanal 
dissection using a conventional retractor has clarified the 
surgical/oncological plane. Later during the high lateral 
dissection, the autonomic nerves, ureters, and pelvic ves-
sels are at risk. In case of major bleeding, tamponade by 
a transanally inserted gauze and positioning the patient 
in reverse Trendelenburg help control and repair vascular 
injury, which may be completed laparoscopically.
This consensus strongly recommended proper training, 
including participation in dedicated courses and proctor-
ing of the first cases before embarking on independent 
practice of TaTME. Guidance from surgeons experienced 
in TaTME help new adopters of the technique avoid mis-
takes made in the past and progress at an efficient pace 
with more appropriate and specialised equipment becom-
ing widely available. To start a TaTME practice, a minimal 
annual volume of 10 complete TME dissections for cancer 
was agreed on. This figure, although low, was felt the least 
to achieve but many voiced concerns that more may be 
required to obtain best possible results. A minimum learn-
ing curve of 20 cases performed within about 2 years was 
felt reasonable, while it was recognized that individual 
variability may influence the length and steepness of the 
learning curve. Experience of the surgeon and his team 
should be considered when reporting and appraising out-
comes. Importantly, participation to an international reg-
istry and/or clinical trial is encouraged to share experi-
ence and benchmark one’s practice with other surgeons 
and institutions.
Whilst this consensus did focus on malignant pathologies 
requiring TME, this new approach may be applied for benign 
conditions as well, although this emerging indication was 
beyond the scope of the present consensus. Several reports 
have shown benefits of a transanal approach beyond cancer 
[54–58], with 11.9% of the cases reported in the TaTME reg-
istry [48] addressing benign conditions. Most benign proce-
dures were an intersphincteric amputation or a proctectomy 
with ileal-pouch-anal reconstruction for inflammatory bowel 
disease. A transanal approach facilitates proctectomy, espe-
cially in obese patients with narrow pelvis. Also, it allows an 
exact transection of the rectum at the top of the anal canal, 
leaving no rectal mucosa behind, and avoids multiple stapler 
firings and cross-stapling. Further benign indications include 
complex fistulae [59, 60], anastomotic complications (ste-
nosis or leakage) [61–63], completion proctectomy [64–66], 
deep pelvic endometriosis [67], and reversal of Hartmann 
[68].
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Conclusion
A broad international consensus statement is presented 
herein, which provides a basis for optimal clinical practice. 
This multidisciplinary consensus statement achieved more 
than 80% approval and can thus be graded as strong rec-
ommendation, yet acknowledging the current lack of high 
level evidence. It provides the best possible guidance to safe 
implementation of Transanal Total Mesorectal Excision.
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